ArticleItalian journal of pediatrics2025
Implementation of the 2022 AAP guidelines for neonatal hyperbilirubinemia could reduce the need for phototherapy in Italy.
Article in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Impact of an institutional guideline on post-discharge follow-up for neonatal hyperbilirubinaemia: a before-and-after cohort study.BMC pediatrics · 2026Article
- Clinical, economic, and organisational impact of the novel AAP 2022 neonatal hyperbilirubinemia guidelines in an Italian third-level neonatology unit.European journal of pediatrics · 2026Observational
- Comparison of Phototherapy and Exchange Transfusion Thresholds According to the Turkish Neonatology Society and the 2022 American Academy of Pediatrics Guidelines in Neonates with Indirect Hyperbilirubinemia.Children (Basel, Switzerland) · 2026Article
- Quality and reliability of neonatal jaundice short videos on TikTok and Bilibili.BMC pediatrics · 2026Article
- Article
- Neonatal hyperbilirubinemia: past lessons, current practices, and future directions.European journal of pediatrics · 2025Review
- Impact of the 2022 American Academy of Pediatrics Hyperbilirubinemia Guideline on Hospitalization Rates and Short-Term Outcomes: A Single-Center Study.Turkish archives of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe American Academy of Pediatrics (AAP) revised in 2022 its guideline on the management of neonatal hyperbilirubinemia and suggested a significant increase in the thresholds for phototherapy. Our aim was to evaluate if the implementation of these guideline could reduce admissions for hyperbilirubinemia requiring phototherapy in our unit.
methodsWe studied 876 infants with gestational age ≥ 35 weeks who were admitted for hyperbilirubinemia requiring phototherapy during the first week of life. Total serum bilirubin (TSB) at the start of phototherapy, which was decided based on the guidelines of the Italian Society of Neonatology, was compared with the TSB thresholds recommended by AAP 2022 guidelines.
resultsSeven hundred and thirteen (82%) infants had TSB at the start of phototherapy lower than AAP 2022 threshold (16.2 ± 3.0 vs. 17.7 ± 3.4 mg/dL; P < 0.001) with a mean difference of 1.8 (0.7-2.6) mg/dL. Among them, one hundred and fifteen infants (13%), 226 (26%), and 372 (42%) had TSB slightly (0.1-1-0 mg/dL), moderately (1.1-2.0 mg/dL), or greatly (> 2.0 mg/dL) below AAP threshold.
conclusionsIt can be estimated that the implementation of the AAP 2022 guidelines in our unit could reduce the rate of hospitalizations for hyperbilirubinemia requiring phototherapy by 42 to 68%. These findings, along with the short- and long-term neonatal and economic benefits, support the implementation of the AAP 2022 guidelines in our unit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.